Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exendin-4 in Alzheimer's Disease
NCT01255163Phase 2Terminated
- Sponsor
- National Institute on Aging
- Start
- Nov 2010
- Primary completion
- Nov 2016
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of exenatide in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by National Institute on Aging. Primary endpoint: Number of Participants With Incidence of Nausea at 18 months. Started Nov 2010; status: terminated.
02
Drugs
exenatide
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT01255163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01255163.